By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Second interchangeable biosimilar product approved by agency
The division is expected to grow to over a 100-member strong team by 2022
It is the first presbyopia-correcting lens implant for cataract surgery
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Subscribe To Our Newsletter & Stay Updated
